Targeting the tumour stroma to improve cancer therapy
Targeting the tumour stroma to improve cancer therapy, Published online: 12 April 2018; doi:10.1038/s41571-018-0007-1The tumour stroma is a component of the tumour microenvironment and has crucial roles in tumour initiation, progression, and metastasis. Most anticancer therapies target cancer cells specifically, but the tumour stroma can promote resistance to such therapies. Herein, the authors provide an overview of the complex cancer cell–tumour stroma interactions and discuss how novel treatment strategies should combine anticancer and antistromal agents. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 12, 2018 Category: Cancer & Oncology Authors: Kenneth C. Valkenburg Amber E. de Groot Kenneth J. Pienta Source Type: research
MRI improves diagnosis
MRI improves diagnosis, Published online: 11 April 2018; doi:10.1038/s41571-018-0013-3MRI improves diagnosis (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Current state of immunotherapy for glioblastoma
Current state of immunotherapy for glioblastoma, Published online: 11 April 2018; doi:10.1038/s41571-018-0003-5Glioblastoma is a disease associated with a dismal patient prognosis, necessitating the development of novel therapies. Substantial research effort is being devoted to the development of immunotherapies for glioblastoma. Herein, the rationale and promise for this approach are discussed, together with the challenges and how they might be overcome. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 11, 2018 Category: Cancer & Oncology Authors: Michael Lim Yuanxuan Xia Chetan Bettegowda Michael Weller Source Type: research
The gut microbiota influences anticancer immunosurveillance and general health
The gut microbiota influences anticancer immunosurveillance and general health, Published online: 10 April 2018; doi:10.1038/s41571-018-0006-2Emerging evidence indicates that the composition of the intestinal microbiota influences anticancer immunosurveillance and therefore the effectiveness of anticancer therapies, especially immune-checkpoint inhibitors. Herein, key contributors to this field of research discuss these connections between gut bacteria, anticancer immunity, and general health, with a focus on specific bacterial species consistently associated with favourable clinical outcomes of anticancer immunotherapy, a...
Source: Nature Clinical Practice Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Bertrand Routy Vancheswaran Gopalakrishnan Romain Daill ère Laurence Zitvogel Jennifer A. Wargo Guido Kroemer Source Type: research
Obesity associated with resistance to anti-angiogenic therapy
Obesity associated with resistance to anti-angiogenic therapy, Published online: 06 April 2018; doi:10.1038/s41571-018-0011-5Obesity associated with resistance to anti-angiogenic therapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Improved pain management
<i>Improved pain management</i>
, Published online: 06 April 2018; doi:10.1038/s41571-018-0010-6
Improved pain management (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Precision oncology in non-small-cell lung cancer: opportunities and challenges
Precision oncology in non-small-cell lung cancer: opportunities and challenges, Published online: 29 March 2018; doi:10.1038/s41571-018-0008-0Major advances in our understanding of the molecular pathogenesis of non-small-cell lung cancer (NSCLC) have led to effective targeted therapeutics in several genomically-defined subsets of NSCLC. The recently updated College of American Pathologists, International Association for the Study of Lung cancer, and Association for Molecular Pathology joint guideline, which was endorsed by ASCO, sets new standards for molecular testing in NSCLC. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Chul Kim Giuseppe Giaccone Source Type: research
The emerging clinical relevance of genomics in cancer medicine
The emerging clinical relevance of genomics in cancer medicine, Published online: 29 March 2018; doi:10.1038/s41571-018-0002-6Developments in genomic sequencing technologies have enabled increasing amounts of information on the genomes of individual cancers to be revealed. At the same time, increasing numbers of therapies targeting specific genomic alterations are being made available, necessitating the use of genomics to diagnose and treat patients with cancer. In this Review, the authors describe the emerging clinical relevance of genomics in oncology, in addition to the many challenges that currently preclude routine cl...
Source: Nature Clinical Practice Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Michael F. Berger Elaine R. Mardis Source Type: research
DDR signature to predict response to ICI
DDR signature to predict response to ICI, Published online: 28 March 2018; doi:10.1038/s41571-018-0005-3DDR signature to predict response to ICI (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
PET imaging reveals EGFR mutation status
PET imaging reveals <i>EGFR</i> mutation status, Published online: 28 March 2018; doi:10.1038/s41571-018-0009-zPET imaging reveals EGFR mutation status (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 28, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Breast cancer: Changes in clonal dynamics predict response to palbociclib
Breast cancer: Changes in clonal dynamics predict response to palbociclib, Published online: 20 March 2018; doi:10.1038/nrclinonc.2018.42Breast cancer: Changes in clonal dynamics predict response to palbociclib (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Paediatric cancer: Pan-cancer genomic analyses uncover molecular drivers
Paediatric cancer: Pan-cancer genomic analyses uncover molecular drivers, Published online: 20 March 2018; doi:10.1038/nrclinonc.2018.43Paediatric cancer: Pan-cancer genomic analyses uncover molecular drivers (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 20, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Triple-negative breast cancers — a panoply of cancer types
Triple-negative breast cancers — a panoply of cancer types, Published online: 19 March 2018; doi:10.1038/s41571-018-0001-7The biological complexity of triple-negative breast cancers (TNBCs) and the lack of highly recurrent targetable genetic alterations pose major challenges for the implementation of targeted therapies for this disease. A recent multiomic in silico study has identified genetic drivers of five different TNBC molecular subtypes, providing new opportunities for precision medicine approaches. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 19, 2018 Category: Cancer & Oncology Authors: Fresia Pareja Jorge S. Reis-Filho Source Type: research
A call for pragmatism in cancer research
A call for pragmatism in cancer research, Published online: 19 March 2018; doi:10.1038/nrclinonc.2018.41A call for pragmatism in cancer research (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 19, 2018 Category: Cancer & Oncology Source Type: research
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.40Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
